Literature DB >> 17077428

Progression of mild cognitive impairment to dementia: a challenge to current thinking.

Anja Busse1, Matthias C Angermeyer, Steffi G Riedel-Heller.   

Abstract

BACKGROUND: Studies of conversion from mild cognitive impairment to dementia suggest a linear progression over time. Conversion rates during lifetime may extend to 80-90%. AIMS: This study examines the time-dependent evolution from mild cognitive impairment to dementia. Current assumptions regarding yearly and lifetime conversion rates are challenged.
METHOD: A community sample of 1045 dementia-free individuals aged 75 years and over was examined by neuropsychological testing based on 6 years of observation.
RESULTS: Approximately 60-65% of people with mild cognitive impairment develop clinical dementia during their life. Progression from mild cognitive impairment to dementia appears to be time dependent, occurring primarily within the initial 18 months.
CONCLUSIONS: Further long-term studies are needed to examine the time-dependent evolution from mild cognitive impairment to dementia and to establish age-specific conversion rates during lifetime.

Entities:  

Mesh:

Year:  2006        PMID: 17077428     DOI: 10.1192/bjp.bp.105.014779

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  33 in total

Review 1.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

2.  The impact of MRI combined with visual rating scales on the clinical diagnosis of dementia: a prospective study.

Authors:  Martijn V Verhagen; Gerard L Guit; Gerrit Jan Hafkamp; Kees Kalisvaart
Journal:  Eur Radiol       Date:  2015-08-29       Impact factor: 5.315

Review 3.  Treatment for mild cognitive impairment: systematic review.

Authors:  Claudia Cooper; Ryan Li; Constantine Lyketsos; Gill Livingston
Journal:  Br J Psychiatry       Date:  2013-09       Impact factor: 9.319

Review 4.  Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.

Authors:  Andrea C Tricco; Charlene Soobiah; Shirra Berliner; Joanne M Ho; Carmen H Ng; Huda M Ashoor; Maggie H Chen; Brenda Hemmelgarn; Sharon E Straus
Journal:  CMAJ       Date:  2013-09-16       Impact factor: 8.262

5.  Deep sparse multi-task learning for feature selection in Alzheimer's disease diagnosis.

Authors:  Heung-Il Suk; Seong-Whan Lee; Dinggang Shen
Journal:  Brain Struct Funct       Date:  2015-05-21       Impact factor: 3.270

6.  Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline.

Authors:  Nare Torosyan; Kelsey Mason; Magnus Dahlbom; Daniel H S Silverman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-22       Impact factor: 9.236

7.  Prognosis of mild cognitive impairment in general practice: results of the German AgeCoDe study.

Authors:  Hanna Kaduszkiewicz; Marion Eisele; Birgitt Wiese; Jana Prokein; Melanie Luppa; Tobias Luck; Frank Jessen; Horst Bickel; Edelgard Mösch; Michael Pentzek; Angela Fuchs; Sandra Eifflaender-Gorfer; Siegfried Weyerer; Hans-Helmut König; Christian Brettschneider; Hendrik van den Bussche; Wolfgang Maier; Martin Scherer; Steffi G Riedel-Heller
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

8.  Structured approach to patients with memory difficulties in family practice.

Authors:  Linda Lee; W Wayne Weston; George Heckman; Micheline Gagnon; F Joseph Lee; Scott Sloka
Journal:  Can Fam Physician       Date:  2013-03       Impact factor: 3.275

9.  Persistence of neuropsychological testing deficits in mild cognitive impairment.

Authors:  Edmond Teng; Kathleen D Tingus; Po H Lu; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2009-08-26       Impact factor: 2.959

10.  Demographic and clinical characteristics of middle-aged versus younger adults enrolled in a clinical trial of a web-delivered psychosocial treatment for substance use disorders.

Authors:  Raj K Kalapatapu; Aimee Campbell; Efrat Aharonovich; Mei-Chen Hu; Frances R Levin; Edward V Nunes
Journal:  J Addict Med       Date:  2013 Jan-Feb       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.